Lexeo Therapeutics, INC Form 4 insider transactions

Lexeo Therapeutics' Chief Financial Officer, Louis Edward Tamayo, reported a sale of 4,641 shares of common stock on July 1, 2026, for a weighted average price of $4.49 per share.

Lexeo Therapeutics' Chief Operating Officer, Jose Manuel Otero, reported transactions involving the acquisition and sale of company common stock.

Lexeo Therapeutics Chief Medical Officer Narinder Pal Bhalla reported a transaction involving the sale of company stock.

Richard Nolan Townsend, CEO and Director of Lexeo Therapeutics, sold 25,947 shares of common stock to cover tax obligations related to the release of Restricted Stock Units.

Lexeo Therapeutics Director Steven Altschuler acquired 35,000 stock options with an exercise price of $4.70, vesting under specific conditions.

Mette Kirstine Agger, a Director at Lexeo Therapeutics, Inc., acquired 35,000 stock options.

Lexeo Therapeutics, Inc. reports that Director Brenda Cooperstone acquired stock options for 35,000 shares of common stock.

Lexeo Therapeutics Director Reinaldo M. Diaz acquired 35,000 stock options with an exercise price of $4.70, vesting one year from the grant date or at the next annual meeting.

Lexeo Therapeutics, Inc. reports that Director Tolga Tanguler acquired stock options for 35,000 shares of common stock.

Lexeo Therapeutics Director Timothy Van Hauwermeiren acquired 35,000 stock options with an exercise price of $4.70, vesting under specific conditions.

Lexeo Therapeutics, Inc. reports that Director Paula H. Cholmondeley was granted stock options for 35,000 shares.

Lexeo Therapeutics Chief Operating Officer Jose Manuel Otero sold 1,302 shares of common stock for $5.074 per share, totaling $6,607, to cover tax obligations on restricted stock units.

Richard Nolan Townsend, CEO and Director of Lexeo Therapeutics, reported a sale of 3,342 shares of common stock to cover tax obligations related to restricted stock units.

Lexeo Therapeutics CEO Richard Nolan Townsend sold 55,000 shares of common stock for approximately $5.69 per share, as part of a pre-arranged trading plan.

Lexeo Therapeutics CEO Richard Nolan Townsend acquired 2,623 shares of common stock through the company's Employee Stock Purchase Plan.

Lexeo Therapeutics' Chief Operating Officer, Jose Manuel Otero, acquired 5,930 shares of common stock through the company's Employee Stock Purchase Plan.

Lexeo Therapeutics CEO Richard Nolan Townsend received substantial equity grants, including restricted stock units and stock options, aligning his interests with shareholders.

Lexeo Therapeutics' Chief Operating Officer, Jose Manuel Otero, was granted 65,000 Restricted Stock Units and 260,000 stock options, vesting over several years.

Lexeo Therapeutics' Chief Financial Officer, Louis Edward Tamayo, acquired 44,665 restricted stock units and 226,665 stock options as part of compensation.

Lexeo Therapeutics CEO Richard Nolan Townsend sold 1,127 shares of common stock to cover tax obligations related to restricted stock units.

Lexeo Therapeutics' Chief Medical Officer, Eric Adler, sold 615 shares of common stock on November 18, 2025, to cover tax obligations related to restricted stock units.

Lexeo Therapeutics' Chief Development Officer, Sandi See Tai, reported a planned sale of 386 common stock shares on November 18, 2025, at a weighted average price of $9.27 to cover tax obligations from restricted stock units.

Lexeo Therapeutics' Chief Legal Officer, Jenny Robertson, sold 549 shares of common stock to cover tax obligations related to restricted stock units.

Lexeo Therapeutics' Chief Technical Officer, Jose Manuel Otero, sold 721 shares of common stock at a weighted average price of $9.27 to cover tax obligations related to restricted stock units.

Lexeo Therapeutics' Chief Development Officer, See Tai Sandi, reported the acquisition of common stock and subsequent sales to cover tax obligations related to Restricted Stock Units.

Lexeo Therapeutics' Chief Legal Officer, Jenny Robertson, executed pre-planned transactions, acquiring shares and selling a portion to cover tax obligations from RSU vesting.

Lexeo Therapeutics' Chief Technical Officer, Jose Manuel Otero, sold a portion of his common stock to cover tax obligations following an RSU vesting.

Lexeo Therapeutics' Chief Medical Officer, Eric Adler, reported the acquisition of shares and subsequent sale of a portion to cover tax obligations related to RSU vesting.

Lexeo Therapeutics CEO Richard Nolan Townsend reported the acquisition of 33,000 shares and subsequent sale of 13,133 shares to cover tax obligations related to Restricted Stock Unit vesting.

Lexeo Therapeutics CEO Richard Nolan Townsend acquired 2,193 shares of common stock at $2.644 per share through the company's Employee Stock Purchase Plan.